An open, observational, non-interventional, multicenter study of the effect of Kagocel® on the quality of life of patients with acute respiratory viral infections in realworld clinical practice in the Republic of Kazakhstan

Relevance. Acute respiratory infections are the leading cause of disease worldwide. Kagocel® is a synthetic antiviral agent indicated for influenza and other acute respiratory viral infections (ARVI). It induces the production of interferon, thereby enhancing the immune response to viral pathogens.

Objective. To evaluate changes in quality of life and symptom dynamics when prescribing Kagocel® to patients with ARVI.

Materials and methods. This open, multicenter, observational, non-interventional study enrolled 1000 adult patients, 467 with mild and 533 with moderate ARVI. All patients were prescribed Kagocel® tablets for 4 days within 24–72 h from the ARVI symptom onset.

Results. In patients with mild ARVI, a statistically significant (p <0,001) improvement in the EuroQol-5 Dimension 3-level (EQ-5D-3L) score was observed by day 3, with scores increasing from 84.3±10.0 to 90.4±5.1 on day 3 and further to 95.7±4.9 by day 6. Similarly, in patients with moderate ARVI, there was also a statistically significant (p <0,001) improvement noted by day 3, with scores rising from 70.4±13.6 to 85.4±8.2 on day 3 and reaching 99.1±3.7 by day 6. By days 3 and 6, 22.1% and 88.0% of patients with mild ARVI, respectively, had no remaining symptoms. By day 3, 10.5% of patients with moderate ARVI undergoing therapy reported the absence of ARVI symptoms, and 89.9% of patients were symptom-free by day 6. No adverse events were reported.

Conclusion. The oral administration of Kagocel® to ambulatory patients with mild to moderate ARVI was effective and safe; therefore, it may be routinely recommended.

1. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016 Oct 8;388(10053): 1545-1602. doi: 10.1016/S0140-6736(16)31678-6. Erratum in: Lancet. 2017 Jan 7;389(10064):e1. doi: 10.1016/S0140-6736(16)32606-X.

2. GBD 2016 Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018 Nov;18(11):1191-1210. doi: 10.1016/S1473-3099(18)30310-4.

3. Um S., Vang D., Pin P., Chau D. Trends and determinants of acute respiratory infection symptoms among under-five children in Cambodia: Analysis of 2000 to 2014 Cambodia demographic and health surveys. PLOS Glob Public Health. 2023 May 3;3(5):e0001440. doi: 10.1371/journal.pgph.0001440.

4. Cui C., Timbrook T.T., Polacek C., et al. Disease burden and high-risk populations for complications in patients with acute respiratory infections: a scoping review. Front Med (Lausanne). 2024 May 16;11:1325236. doi: 10.3389/fmed.2024.1325236.

5. Zhang S., Wahi-Singh P., Wahi-Singh B., et al; RESCEU Investigators. Costs of management of acute respiratory infections in older adults: A systematic review and meta-analysis. J Glob Health. 2022 Nov 8;12:04096. doi: 10.7189/jogh.12.04096.

6. Fediakina I.T., Konopleva M.V., Proshina E.S., et al. Antiviral effect of «Kagocel» substance in vitro on influenza viruses H1N1, H1N1PDM09 and H3N2. Problems of Virology. 2019;64(3):125-131. (In Russ.).

7. Borovskaya T.G. Safety of the Russian antiviral drug Kagocel. Ter Arkh. 2017;89(11):93–99 (In Russ.) doi: 10.17116/terarkh2017891193-99.

8. Fazylov V.C., Sitnikov I.G., Malyshev N.A., et al. The effect of antiviral therapy on the incidence of bacterial aggravations and administration of systemic antibiotics in patients with acute respiratory viral infections and influenza (results of international cohort observational study). Antibiot Khimioter. 2016;61(11–12):39–47 (In Russ.).

9. Merkulova L.N., Kolobukhina L.V., Kistenova L.B., et al. Therapeutic efficacy of Kagocel in the treatment of patients with uncomplicated influenza and influenza complicated by angina. Clin Phar Macol Ther. 2002;11(5):21–3 (In Russ.).

10. Logvinenko I.I., Voevoda M.I. Therapy of acute respiratory diseases with those operating under conditions of low intensity occupational hazards. Cons Medicum. 2016;18(3):24–9 (In Russ.).